495 results about "Anxiety disorder" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The invention provides an application of a fermentation lactobacillus mucus strain A21196 in preparation of a product for resisting anxiety and improving memory and concentration, and belongs to the technical field of biological medicines. Animal experiments show that the fermented lactobacillus mucus strain A21196 has the effects of resisting anxiety, resisting depression, improving cognitive impairment function and improving memory concentration, and provides a new means for preventing and / or treating nerve diseases related to anxiety disorder, depression and cognitive impairment.

A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and / or measures of depression (HDRS or BDI scores) and / or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.

A method of predicting neural activation and psychopathology, indicative of ADHD and mood and anxiety disorders in a subject, such as children, is disclosed. The method may be implemented via computer software on a tablet computer, laptop or desktop computer, an input device, such as touchscreen, keyboard or mouse, and a camera. The camera is positioned to capture the subject's face in the frame of the camera. A frustration-inducing activity, such as a game, to the subject, where the subject received positive or negative feedback based on the selections they make in a game. The subject's reactions to the feedback are captured and parsed by the software, to determine the subject's emotional reaction to feedback. Reactions such as eye gaze, head pose, and facial expression may be used. Over a number of trials of the game, a prediction may be made for the neural activation and psychopathology of the subject.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The present disclosure provides a method of treating a symptom or preventing a symptom of generalized anxiety disorder comprising administering an orally disintegrating tablet comprising LSD, or a salt thereof, to a subject in need thereof.

The invention belongs to the technical field of microorganisms, and relates to high-activity plant lactobacillus KL100 for relieving anxiety and depression and application of the high-activity plant lactobacillus KL100. The plant lactobacillus provided by the invention is KL100, is preserved in the China General Microbiological Culture Collection Center (CGMCC), has a preservation number of CGMCC No.27192, and is classified and named as the plant lactobacillus. The plant lactobacillus is KL100, has a good gastrointestinal passing rate, shows a breeding characteristic in the stomach after being embedded, is improved in cholate-resistant survival rate, and can be used for preparing the plant lactobacillus. According to the application disclosed by the invention, the expression of IL-1beta and TNF-alpha in a mouse body can be effectively reduced, the expression of IL-10 can be improved, and the secretion of 5-hydroxytryptamine by chromaffin cells in intestinal tracts can be promoted, so that anxiety and depression can be relieved, the strain resource is expanded, the development of the biological medicine field is promoted, and a new direction is provided for treating anxiety and depression.

The invention discloses an anxiety disorder diagnosis and treatment assisting and relieving system of a massage chair. The anxiety disorder diagnosis and treatment assisting and relieving system comprises a multi-mode biological signal collection function, an emotion detection and analysis function, an intelligent massage function and a feedback function. The anxiety state of the user can be comprehensively monitored by fusing multi-modal physiological signals such as body temperature, heart rate, skin conductivity and respiratory rate, and multi-dimensional real-time evaluation of the anxiety state of the user is realized by combining facial expression and voice emotion recognition. According to the anxiety degree, the intelligent massage system of the chair can automatically adjust the massage strength and mode to help the user to effectively relieve physical and mental pressure. Meanwhile, a built-in system can record physiological data and emotion changes of the user to form a health record, and change and improvement of anxiety disorder can be tracked conveniently for a long time.

The invention discloses a traditional Chinese medicine composition for treating depression as well as a preparation method and application of the traditional Chinese medicine composition. The preparation method comprises the following steps: weighing vinegar-processed rhizoma cyperi, ligusticum wallichii, fried rhizoma atractylodis, fried medicated leaven and fried fructus gardeniae which are equal in mass; crushing and sieving the vinegar rhizoma cyperi, the ligusticum wallichii, the fried rhizoma atractylodis and the fried medicated leaven to obtain traditional Chinese medicine powder; placing the traditional Chinese medicine powder in a 60-80% ethanol solution for decoction extraction, filtering, collecting filtrate, repeatedly extracting for 2-4 times, merging the filtrate, concentrating and drying to obtain thick paste; the fried cape jasmine is smashed and sieved, cape jasmine powder is obtained, then the cape jasmine powder and the thick paste are mixed, and the traditional Chinese medicine composition for treating depression is obtained. The preparation method disclosed by the invention can be used for efficiently and fully extracting active ingredients, such as ligustilide, atractydin I and alpha-cyperone, in the traditional Chinese medicine raw materials to obtain a new extract which is excellent in medicine effect, clear in ingredients and free from obvious toxic and side effects, and is expected to be developed as a novel medicine for improving and / or treating depression and anxiety disorder.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The invention discloses a non-invasive electrical stimulation regulation and control system and a method thereof. The regulation and control system comprises an electroencephalogram acquisition module, an individualized parameter extraction module and a regulation and control module, wherein the individualized parameter extraction module is composed of a frequency extraction unit and a site determination unit; the electroencephalogram acquisition module is used for acquiring and recording resting-state electroencephalogram signals of an anxiety disorder patient; the individualized parameter extraction module is used for extracting an individual alpha frequency and an individualized stimulation site of a patient; wherein the frequency extraction unit selects a frequency at a peak value of a power spectrum as an individual alpha frequency through spectrum analysis; the site determination unit selects a site with the weakest function connection as a personalized stimulation site by calculating the PLV value of the frontal apex lobe network; the regulation and control module is used for outputting a personalized stimulation scheme and implementing non-invasive transcranial electrical stimulation, and more personalized and accurate regulation and control on anxiety disorder patients are achieved by considering the difference between individuals.

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Methods, systems and devices for reducing anxiety, including increasing relaxation and / or calm. In some variations these methods may include reducing anxiety, increase relaxation and / or calm by non-invasive temperature regulation of the frontal cortex prior to and / or during sleep. The subject may have an anxiety disorder, or may not have a diagnosed anxiety disorder.

The invention provides a method for constructing a chronic unpredictable negative stress model, the chronic unpredictable negative stress model and application of the chronic unpredictable negative stress model in mental disease research, and belongs to the field of brain organ in-vitro model construction. Through dual verification of a microelectrode array and single cell sequencing, an in-vitro brain organ model capable of simulating chronic unpredictable negative stress core characteristics is successfully constructed, and a potential neural network function reconstruction mechanism and a cell molecule basis of the in-vitro brain organ model are disclosed. The comprehensive research normal form breaks through the limitation of a traditional single technology platform, and an accurate and efficient innovative research platform highly related to human is provided for pathogenesis research of mental diseases, especially chronic stress related diseases such as depression and anxiety and development of novel treatment strategies.

The invention relates to a treatment method for realizing TMS treatment for mood disorder and anxiety disorder based on emotion induction. The treatment method comprises the following steps: performing clinical assessment on mental and psychological states of a patient before treatment; performing brain magnetic resonance examination processing on the patient based on the emotion induction state; performing priority ranking processing on the selected individualized target spots according to the clinical evaluation of the patient and the abnormal degree of the brain function activity under emotion induction; a TMS treatment scheme under the emotion induction scene is formulated according to the target priority arrangement sequence; performing treatment evaluation in a short-term time period, and performing long-term prediction of a future residual treatment trajectory by using the curative effect prediction model; after treatment is finished, a treatment track is fed back to the local database, and clinical evaluation after treatment is carried out. The invention further relates to a corresponding device, a processor and a storage medium. By adopting the method, the device, the processor and the storage medium, the contrast difference of the patient in different situations can be effectively displayed through the situational stimulation library and the situational brain function image.

The invention relates to the field of breeding technical equipment, and particularly provides protein expression profile screening and application of anxiety disorder of Alzheimer's disease. Specifically, for Alzheimer's disease anxiety disorder caused by amyloid beta protein accumulation, proteomics analysis finds that inhibition of aBLA-vCA1 pathway functions can effectively relieve social avoidance behaviors caused by amyloid beta protein accumulation; and the differential functional proteins of the anxiety disorder of the Alzheimer's disease, such as RPS6, UBQLN1, Eras2, Rpl30, SERBP1, CLU, APOE, C4B, C1QB, C1QA, C1QC, MAPK1, MAPK3, RHOG, PTK2B, ASPA, GAD1, GAD2, H3f3a, H4C8 and TSPYL4, are screened out. The different functional proteins can be used as biomarkers for detecting Alzheimer's disease anxiety disorder caused by accumulation of pulverulent beta protein, and can be used as potential therapeutic targets.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention relates to Ackermann muciniphile as well as a regulator and application thereof, and relates to the technical field of biochemistry. The invention provides application of ackermann muciniphile in preparation of drugs for treating anxiety, and the ackermann muciniphile can significantly improve exploration interest, significantly reduce anxiety level and reverse anxiety manifestation caused by chronic stress, which indicates that the ackermann muciniphile has an effect of treating anxiety. The invention also provides an application of the regulator in preparation of medicines or health-care foods for regulating intestinal flora. The regulator comprises cape jasmine and fermented soybean soup. The regulator can obviously increase the quantity of Ackerman muciniphile in the intestinal tract of a mouse, so that the intestinal health is improved, and the micro-ecological balance of the intestinal tract of a human body is regulated.

The invention provides an application of a pediococcus pentosaceus strain A20001 in preparation of a product for improving memory concentration and anxiety and depression behaviors, and belongs to the technical field of biological medicines. Animal experiments show that the pediococcus pentosaceus strain A20001 has the functions of resisting anxiety behavior, resisting depression, improving cognitive function and improving memory concentration. Therefore, the invention provides the application of the pediococcus pentosaceus strain A20001 in the preparation of the medicine for preventing and / or treating the anxiety disorder, the depression or the cognitive impairment and improving the memory, and further provides the application of the pediococcus pentosaceus strain A20001 in the preparation of the medicine for preventing and / or treating the anxiety disorder, the depression or the cognitive impairment.

This invention pertains to a cognitive-coping therapy (CCT) method, system, and application that is a computer-implemented method for implementing AI-based CCT for a patient using natural language processing (NLP) and / or human-machine dialogue with / without an avatar. Based on the cognitive psychology and stress-coping theory, the CCT alleviates the excessive fear of negative event(s) and can be used to address mental disorders / conditions like obsessive-compulsive disorder (OCD), anxiety disorders (e.g., panic disorder, social phobia), and more. The AI system uses the NLP to comprehend the patient's symptoms and provide relevant interventions. Additionally, the system can monitor the patient's progress over time and adapt the interventions accordingly.

The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.